Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia
Open accessThe DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Abstract
Metabolic-associated fatty liver disease (MAFLD) is the most prevalent chronic liver disease worldwide, affecting 25% of people globally and up to 80% of people with obesity. MAFLD is characterised by fat accumulation in the liver (hepatic steatosis) with varying degrees of inflammation and fibrosis. MAFLD is strongly linked with cardiometabolic disease and lifestyle-related cancers, in addition to heightened liver-related morbidity and mortality. This position statement examines evidence for exercise in the management of MAFLD and describes the role of the exercise professional in the context of the multi-disciplinary care team. The purpose of these guidelines is to equip the exercise professional with a broad understanding of the pathophysiological underpinnings of MAFLD, how it is diagnosed and managed in clinical practice, and to provide evidence- and consensus-based recommendations for exercise therapy in MAFLD management. The majority of research evidence indicates that 150–240 min per week of at least moderate-intensity aerobic exercise can reduce hepatic steatosis by ~ 2–4% (absolute reduction), but as little as 135 min/week has been shown to be effective. While emerging evidence shows that high-intensity interval training (HIIT) approaches may provide comparable benefit on hepatic steatosis, there does not appear to be an intensity-dependent benefit, as long as the recommended exercise volume is achieved. This dose of exercise is likely to also reduce central adiposity, increase cardiorespiratory fitness and improve cardiometabolic health, irrespective of weight loss. Resistance training should be considered in addition to, and not instead of, aerobic exercise targets. The information in this statement is relevant and appropriate for people living with the condition historically termed non-alcoholic fatty liver disease (NAFLD), regardless of terminology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Schematic definition of MAFLD. Adapted from Eslam 2020 [1], with permission. BMI body mass index, HDL-cholesterol high-density lipoprotein-cholesterol, HbA1c glycated haemoglobin, HOMA homeostatic model assessment, hs-CRP high-sensitivity C-reactive protein. *Relates to liver histology from liver biopsy, with ≥ 5% referring to the proportion of hepatocytes containing visible intracellular lipid droplets. Other modalities (imaging, blood biomarkers/scores) have assigned thresholds to detect steatosis at ≥ 5%](https://figures.cochat.ai/paper-figures/af922b12fa45496787f49262d52e3ee8/exercise-in-the-management-of-metabolic-associated-fatty-liver-disease-mafld-in-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234 · cited 2×
“…of participants, and a one-stage regression in hepatocyte ballooning in 67% of participants ( n = 12) following 12 weeks of moder-ate-to-vigorous [40–75% heart rate reserve (HRR)] aerobic exercise intervention on 3–5 days per week; however, there was no control group for comparison and there was…”
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Guralnik, J. M., Simonsick, E. M., Ferrucci, L., Glynn, R. J., Berkman, L. F., Blazer, D. G., Scherr, P. A., & Wallace, R. B. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.2.m85 · Cited by 9,792 · cited 1×
“Further clinical assessment to establish sarcopenia [37] and frailty via imaging and/ or relevant clinical measures such as the short physical performance battery (SPPB) [38] may be clinically appropriate to consider based on individual presentation.”
(2014) · Medical Entomology and Zoology · Cited by 9,400
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“…end-stage liver disease and primary liver cancer, MAFLD plays a central role in the development of type 2 diabetes (T2D), cardiovascular disease (CVD) and extrahepatic lifestyle-related cancers [5], reducing life expectancy by 4 years and increasing time spent living with high metabolic burden [6].”
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472 · cited 3×
“MAFLD is defined by the presence of hepatic steatosis in the setting of metabolic dysfunction characterised by having overweight/obesity or T2D, or specific features of metabolic dysregulation [1] (Fig.”
InfluentialSelf-citationBurden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783 · cited 1×
“MAFLD affects at least 25% of people globally and within Australia [2–4].”
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 2×
“Dietary fats, which deliver FFA from the gut via chylomicrons, account for the remaining 15% [13].”
Research works printed but not linked: 3
- European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. https://doi.org/10.1016/j.jhep.2015.11.004. · DOI · Paper page
- Sabag A, Barr L, Armour M, et al. The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2022;107(3):862–81. https://doi.org/10.1210/clinem/dgab795. (published Online First: 2021/11/02). · DOI · Paper page
- Ye YCL, Yang X. The efficacy of resistance training for non-alcoholic fatty liver disease: a meta-anlaysis of randomized controlled trials. Int J Clin Exp Med. 2019;12(2):13188–95.
Cited by
Eslam, M., Fan, J.-G., Yu, M.-L., Wong, V. W.-S., Cua, I. H., Liu, C.-J., Tanwandee, T., Gani, R., Seto, W.-K., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 170
“There are no evidence-supported recommendations regarding the intensity, frequency, number of sets and repetitions of resistance exercise required for hepatic benefit [170].”
InfluentialSelf-citationMiller, D. M., McCauley, K. F., & Dunham‐Snary, K. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70132 · Cited by 152
“Conversely, structured physical activity (e.g., moderate- to-vigorous aerobic exercise for 135–240 min/week) improves hepatic steatosis and reduces intrahepatic triglycerides, even without significant weight loss [24].”
Cól, J. P. D., de Lima, E. P., Pompeu, F. M., Araújo, A. C., Goulart, R. D. Á., Bechara, M. D., Laurindo, L. F., Méndez‐Sánchez, N., & Barbalho, S. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073694 · Cited by 92
“Currently, non-drug treatment for MAFLD is based on changing eating habits, aiming to reduce visceral lipid accumulation, combined with the initiation of physical activity, responsible for reducing the inflammatory markers characteristic of the pathophysiology of the disease [188,189].”
BackgroundBeygi, M., Ahi, S., Zolghadri, S., & Stanek, A. (2024) · Nutrients · doi:10.3390/nu16142220 · Cited by 75
“Incorporating activities such as lifting weights, resistance band exercises, and bodyweight exercises into a workout regimen can be highly beneficial [37].”
BackgroundDua, A., KUMARI, R. R., Singh, M., Kumar, R., Pradeep, S., Ojesina, A. I., & Kumar, R. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1618275 · Cited by 72
Metadata
- Authors
- Keating, S. E., Sabag, A., Hallsworth, K., Hickman, I. J., Macdonald, G. A., Stine, J. G., George, J., & Johnson, N. A.
- Affiliations
- The University of Queensland (AU)
- The University of Sydney (AU)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Pennsylvania State University (US)
- Corresponding author
- Keating, Shelley E.
- ORCID
- Venue
- Sports Medicine
- Published
- 2023-09-11
- Volume
- 53
- Issue
- 12
- Pages
- 2347-2371
- ISSN
- 0112-1642 (ISSN-L)
- 1179-2035
- PMC
- PMC10687186
- OpenAlex
- W4386592430
- Cited by
- 119
- References
- 184
- Citations by year
- 2026: 49 · 2025: 47 · 2024: 22 · 2023: 1
- FWCI
- 23.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Sports Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- The University of Queensland
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Physical Activity and Health
- Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
- Keywords
- metabolic-associated fatty liver disease, exercise therapy, aerobic exercise, high-intensity interval training, resistance training, hepatic steatosis, cardiometabolic health, abdominal obesity, fitness professionals, multidisciplinary care, non-alcoholic fatty liver disease, obesity
- MeSH terms
- Adult, Australia, Exercise Therapy, Humans, Obesity, Sports, Exercise, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia. https://app.cochat.ai/papers/10.1007/s40279-023-01918-w
- The paper
- Keating, S. E., Sabag, A., Hallsworth, K., Hickman, I. J., Macdonald, G. A., Stine, J. G., George, J., & Johnson, N. A. (2023). Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia. Sports Medicine. https://doi.org/10.1007/s40279-023-01918-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.